BR0115883A - Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor - Google Patents

Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor

Info

Publication number
BR0115883A
BR0115883A BR0115883-0A BR0115883A BR0115883A BR 0115883 A BR0115883 A BR 0115883A BR 0115883 A BR0115883 A BR 0115883A BR 0115883 A BR0115883 A BR 0115883A
Authority
BR
Brazil
Prior art keywords
acetic acid
substituted amino
pain
furan
thien
Prior art date
Application number
BR0115883-0A
Other languages
English (en)
Inventor
Corinna Maul
Werner Englberger
Michael Przewosny
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR0115883A publication Critical patent/BR0115883A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

"DERIVADOS DE áCIDO AMINO-FURAN-2-IL-ACéTICO E áCIDO AMINO-TIEN-2-IL-ACéTICO SUBSTITUìDOS E SEU EMPREGO PARA O TRATAMENTO DE CEFALéIA OU DOR". Das fórmulas gerais (I-A) e (I-B). Processos para a sua preparação, medicamentos contendo os mesmos, aplicação destes compostos para a preparação de medicamentos para o tratamento, entre outros, da dor ou cefaléia e composições farmacêuticas contendo os mesmos.
BR0115883-0A 2000-11-30 2001-11-28 Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor BR0115883A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10059864A DE10059864A1 (de) 2000-11-30 2000-11-30 Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate
PCT/EP2001/013910 WO2002044171A1 (de) 2000-11-30 2001-11-28 Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz

Publications (1)

Publication Number Publication Date
BR0115883A true BR0115883A (pt) 2003-12-02

Family

ID=7665508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115883-0A BR0115883A (pt) 2000-11-30 2001-11-28 Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor

Country Status (30)

Country Link
US (1) US6797712B2 (pt)
EP (1) EP1341786B9 (pt)
JP (1) JP4340063B2 (pt)
KR (1) KR20030055334A (pt)
CN (1) CN1326854C (pt)
AR (1) AR035658A1 (pt)
AT (1) ATE418552T1 (pt)
AU (2) AU2073502A (pt)
BR (1) BR0115883A (pt)
CA (1) CA2430280A1 (pt)
CY (1) CY1108871T1 (pt)
CZ (1) CZ20031509A3 (pt)
DE (2) DE10059864A1 (pt)
DK (1) DK1341786T3 (pt)
EC (1) ECSDI034631S (pt)
ES (1) ES2320198T3 (pt)
HK (1) HK1059080A1 (pt)
HU (1) HUP0303041A3 (pt)
IL (2) IL156139A0 (pt)
MX (1) MXPA03004303A (pt)
NO (1) NO20032340L (pt)
NZ (1) NZ526554A (pt)
PE (1) PE20020599A1 (pt)
PL (1) PL362978A1 (pt)
PT (1) PT1341786E (pt)
RU (1) RU2003117703A (pt)
SI (1) SI1341786T1 (pt)
SK (1) SK5942003A3 (pt)
WO (1) WO2002044171A1 (pt)
ZA (1) ZA200305009B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794506B2 (en) * 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
DE10125145A1 (de) * 2001-05-22 2002-11-28 Gruenenthal Gmbh Substituierte C-Furan-2-yl-methylamin- und C-Thiophen-2-yl-methylamin-Derivate
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
DE10306203A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
CA2978188C (en) 2015-03-04 2020-05-12 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN115382297B (zh) * 2022-04-12 2023-10-31 江阴市华思诚无纺布有限公司 熔体直纺双组分pet纺粘液体过滤材料及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000398A1 (en) * 1996-06-28 1998-01-08 University Of Southern California Method for the synthesis of amines and amino acids with organoboron derivatives
US6441237B1 (en) 1999-02-20 2002-08-27 Boehringer Ingelheim Pharma Kg Substituted 3-phenoxy- and 3-phenylalkyloxy-2-phenyl-propylamines
DE19907385A1 (de) * 1999-02-20 2000-08-24 Boehringer Ingelheim Pharma Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds

Also Published As

Publication number Publication date
PT1341786E (pt) 2009-03-31
WO2002044171A1 (de) 2002-06-06
HUP0303041A2 (hu) 2003-12-29
SI1341786T1 (sl) 2009-04-30
NZ526554A (en) 2005-02-25
CN1326854C (zh) 2007-07-18
CZ20031509A3 (cs) 2003-09-17
ES2320198T3 (es) 2009-05-20
CA2430280A1 (en) 2002-06-06
HUP0303041A3 (en) 2007-06-28
US20040030156A1 (en) 2004-02-12
ZA200305009B (en) 2004-08-18
CY1108871T1 (el) 2014-07-02
MXPA03004303A (es) 2003-08-19
NO20032340D0 (no) 2003-05-23
IL156139A (en) 2007-08-19
DE10059864A1 (de) 2002-06-13
EP1341786A1 (de) 2003-09-10
RU2003117703A (ru) 2004-12-10
JP2004526675A (ja) 2004-09-02
AU2002220735B2 (en) 2007-05-10
KR20030055334A (ko) 2003-07-02
HK1059080A1 (en) 2004-06-18
EP1341786B1 (de) 2008-12-24
PE20020599A1 (es) 2002-08-10
ATE418552T1 (de) 2009-01-15
CN1478089A (zh) 2004-02-25
EP1341786B9 (de) 2009-08-05
DK1341786T3 (da) 2009-04-20
SK5942003A3 (en) 2003-11-04
NO20032340L (no) 2003-07-21
IL156139A0 (en) 2003-12-23
DE50114605D1 (de) 2009-02-05
US6797712B2 (en) 2004-09-28
AR035658A1 (es) 2004-06-23
JP4340063B2 (ja) 2009-10-07
AU2073502A (en) 2002-06-11
ECSDI034631S (pt) 2003-07-25
PL362978A1 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
DE69715888D1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
ES2145913T3 (es) Inhibidores de metaloproteasas.
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
DE69535684D1 (de) Zusammensetzungen welche DNA zerstoerende Agentien und P53 enthalten
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
BR9611400A (pt) "agentes antimicobiano de benzoxazina".
BG101118A (en) Therapeutical compounds
LV12632A (lv) Pyrazoline derivatives their preparation and application as medicaments
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ATE83376T1 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
NO975192L (no) Bicykliske aromatiske forbindelser
TR200101649T2 (tr) Piperazin türevleri.
MX9805705A (es) Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
FR2744452B1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
ATE114244T1 (de) Pharmazeutische zusammensetzungen enthaltend fluticasonpropionat und oxikonazol oder dessen salz zur lokalen anwendung.
TR200100637T2 (tr) Yeni doğal ürün türevleri

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 1964 DE 26/08/2008 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS.